- Home
- SSTI vs KPTI Comparison
SSTI vs KPTI Comparison
Compare SSTI & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSTI
- KPTI
- Stock Information
- Founded
- SSTI 1996
- KPTI 2008
- Country
- SSTI United States
- KPTI United States
- Employees
- SSTI N/A
- KPTI N/A
- Industry
- SSTI Computer Software: Prepackaged Software
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- SSTI Technology
- KPTI Health Care
- Exchange
- SSTI Nasdaq
- KPTI Nasdaq
- Market Cap
- SSTI 102.1M
- KPTI 102.4M
- IPO Year
- SSTI 2017
- KPTI 2013
- Fundamental
- Price
- SSTI $8.45
- KPTI $5.54
- Analyst Decision
- SSTI Buy
- KPTI Strong Buy
- Analyst Count
- SSTI 7
- KPTI 6
- Target Price
- SSTI $20.29
- KPTI $22.17
- AVG Volume (30 Days)
- SSTI 115.1K
- KPTI 132.3K
- Earning Date
- SSTI 11-12-2025
- KPTI 11-03-2025
- Dividend Yield
- SSTI N/A
- KPTI N/A
- EPS Growth
- SSTI N/A
- KPTI N/A
- EPS
- SSTI N/A
- KPTI N/A
- Revenue
- SSTI $103,899,000.00
- KPTI $142,530,000.00
- Revenue This Year
- SSTI $11.17
- KPTI $4.87
- Revenue Next Year
- SSTI $9.39
- KPTI $9.20
- P/E Ratio
- SSTI N/A
- KPTI N/A
- Revenue Growth
- SSTI 1.47
- KPTI N/A
- 52 Week Low
- SSTI $7.74
- KPTI $3.51
- 52 Week High
- SSTI $19.43
- KPTI $14.24
- Technical
- Relative Strength Index (RSI)
- SSTI 30.46
- KPTI 44.49
- Support Level
- SSTI $7.73
- KPTI $5.01
- Resistance Level
- SSTI $8.38
- KPTI $5.71
- Average True Range (ATR)
- SSTI 0.54
- KPTI 0.36
- MACD
- SSTI -0.08
- KPTI -0.05
- Stochastic Oscillator
- SSTI 20.88
- KPTI 35.22
About SSTI SoundThinking Inc.
SoundThinking Inc is a public safety technology company that combines transformative solutions and strategic advisory services for law enforcement and civic leadership. Its flagship SafetySmart platform includes ShotSpotter, the acoustic gunshot detection system, CrimeTracer, the foremost law enforcement search engine, CaseBuilder, a one-stop investigation management system, and ResourceRouter, software that directs patrol and community anti-violence resources to help maximize their impact.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.